FCM
ACRS icon

Farallon Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Farallon Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,000
Closed -$2.52M – 298
2021
Q1 		$2.52M Buy
+100,000
New +$1.96M 0.01% 213
2017
Q2 		– Sell
-106,894
Closed -$3.19M – 82
2017
Q1 		$3.19M Buy
+106,894
New +$3.08M 0.04% 69

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Farallon Capital Management's ACRS Position: Q2 2021 in Review

Farallon Capital Management sold out of Aclaris Therapeutics (ACRS) in Q2 2021, closing a stake of 100,000 shares — an estimated $2.52M sold.

Farallon Capital Management first reported a position in ACRS in Q1 2017 and held it in 2 quarters. The position peaked at $3.19M in Q1 2017. 128 funds tracked by Wall St. Rank hold ACRS as of Q2 2021.

  • Farallon Capital Management reported no remaining Aclaris Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Farallon Capital Management sold 100,000 Aclaris Therapeutics shares in Q2 2021, an estimated $2.52M.
  • Farallon Capital Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 2 quarters.
  • Farallon Capital Management's Aclaris Therapeutics position peaked at $3.19M in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.